CasNo.577778-58-6,Topiroxostat,(577778-58-6) Suppliers

1 Kilogram	Negotiable

Min.Order :1 Kilogram
Purity: 99%
Payment Terms : T/T,Other

Keywords

Topiroxostat 577778-58-6 Topiroxostat577778-58-6

Quick Details

Appearance:White Powder
Application:The solubility of topiroxostat in these solvents is approximately 10 and 20 mg/ml, respectively. Uses Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management
PackAge:According to your needs
ProductionCapacity:100|Metric Ton|Day
Storage:storage temperature
Transportation:Courier sea

Superiority:

Boiling point    594.7±60.0 °C(Predicted)
density    1.45±0.1 g/cm3(Predicted)
storage temp.    Store at -20°C
solubility    DMSO : 23.5 mg/mL (94.67 mM; Need ultrasonic and warming)
form    Powder
pka   7.47±0.10(Predicted)
InChI   InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
InChIKey   UBVZQGOVTLIHLH-UHFFFAOYSA-N
SMILES   C1(C#N)=NC=CC(C2NN=C(C3C=CN=CC=3)N=2)=C1Boiling point    594.7±60.0 °C(Predicted)
density    1.45±0.1 g/cm3(Predicted)
storage temp.    Store at -20°C
solubility    DMSO : 23.5 mg/mL (94.67 mM; Need ultrasonic and warming)
form    Powder
pka   7.47±0.10(Predicted)
InChI   InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
InChIKey   UBVZQGOVTLIHLH-UHFFFAOYSA-N
SMILES   C1(C#N)=NC=CC(C2NN=C(C3C=CN=CC=3)N=2)=C1

Details:

Description   Topiroxostat is an orally-administered, non-purine, selective xanthine oxidase (XO) inhibitor developed for the treatment of hyperuricemia specifically for patients with gout in Japan. The drug was discovered and developed by Fuji Yakuhin. In contrast to conventional XO inhibitors such as febuxostat, topiroxostat interacts with key amino acid residues of the solvent channel.
Chemical Properties   Topiroxostat is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of topiroxostat in these solvents is approximately 10 and 20 mg/ml, respectively.
Uses   Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Approved for therapeutic use in Japan since 2013, topiroxostat is marketed under the name Topiloric and Uriadec and is orally administered twice daily.
Biological Activity   Topiroxostat is an inhibitor of xanthine oxidoreductase (IC50 = 5.3 nM), an enzyme that converts xanthine to urate. Formulations containing topiroxostat are effective in vivo, lowering urate levels in the serum of patients with hyperuricemia. In rats, but not primates, topiroxostat treatment results in the formation of xanthine crystals, resulting in nephritis. Topiroxostat also inhibits ATP-binding cassette transporter G2 (ABCG2; IC50 = 0.18 μM), a high-capacity urate transporter that functions in both renal and extrarenal urate secretion.